Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methotrexate in systemic lupus erythematosus

B A Walz LeBlanc1, P Dagenais, M B Urowitz

  • 1Lupus Clinic, Wellesley Hospital, Toronto, ON, Canada.

The Journal of Rheumatology
|May 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Declining levels of serum chemokine (C-X-C motif) ligand 10 over time are associated with new onset of psoriatic arthritis in patients with psoriasis: a new biomarker?

The British journal of dermatology·2020
Same author

Disease course patterns in systemic lupus erythematosus.

Lupus·2018
Same author

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.

Arthritis research & therapy·2018
Same author

Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines.

Arthritis research & therapy·2018
Same author

Severe brady-arrhythmias in systemic lupus erythematosus: prevalence, etiology and associated factors.

Lupus·2018
Same author

Lupus myocarditis: a single center experience and a comparative analysis of observational cohort studies.

Lupus·2018

Methotrexate (MTX) is effective for treating systemic lupus erythematosus (SLE). This study found MTX well-tolerated and beneficial for SLE patients with renal disease or arthritis.

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Methotrexate (MTX) is an established treatment for various autoimmune and inflammatory conditions.
  • Its efficacy in systemic lupus erythematosus (SLE) has not been extensively documented.

Observation:

  • This study retrospectively analyzed MTX therapy in five patients diagnosed with SLE.
  • The patient cohort included individuals with both renal disease and arthritis manifestations of SLE.

Findings:

  • Methotrexate (MTX) therapy demonstrated significant effectiveness in all five SLE patients.
  • The treatment was consistently well-tolerated across the study group, indicating a favorable safety profile.

Implications:

  • Methotrexate (MTX) shows promise as a viable and safe therapeutic option for managing systemic lupus erythematosus (SLE).

Related Experiment Videos

  • Further research into MTX for SLE could lead to expanded treatment guidelines for this complex autoimmune disease.